{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 9,
  "pageCount": 58,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "industry_trends",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 18,
  "notes": "The slide uses stacked bar charts to show the composition of clinical trials by phase (I, II, III) for China and the US.",
  "elementsJson": [
    "headline_text",
    "bar_chart_stacked",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/9",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-9",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Strong growth of trial number in China has been fueled particularly by development of innovative drugs",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-880132633b8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.04,
        "y": 0.215
      },
      "kind": "chart",
      "text": "Number of newly started clinical trials by trial phase (China)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18a95d4e-f166-4755-a49c-55b8911d39fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.04,
        "y": 0.53
      },
      "kind": "chart",
      "text": "Number of newly started clinical trials by trial phase (US)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "674a7290-5ee1-4891-96eb-c058e17c4ae0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Note: *Only including phase 1 to phase 3 trials, while excluding BE and TCM trials, phase 4 trials and IITs. Source: DXY, CPEA (China Pharmaceutical Enterprises Association), L.E.K. research and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09805e4e-c614-411d-9962-228e221c0885",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.53,
        "y": 0.3
      },
      "kind": "list",
      "text": "Strong growth of trial number in China has been fueled particularly by development of innovative drugs. Faster early-stage trial growth, i.e., phase I and II trials, has been witnessed from 2016 to 2021, with a 29% and 47% CAGR respectively.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "961d23dc-caf0-456e-ac22-2a45cf148428",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.53,
        "y": 0.53
      },
      "kind": "list",
      "text": "China has also become a leader of clinical development in certain areas of innovation globally, such as CAR-T and ADC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad35b55c-57a6-4e3b-ac07-325dd7da6c32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "CAGR: 47%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-90770b22936d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.53,
        "y": 0.62
      },
      "kind": "quote",
      "text": "From the view of absolute trial number and growth, China is leading in areas like CAR-T, large molecule, BsAb and ADC globally, with local companies and talents nurtured with the support of policy makers, PEVCs, MNCs, etc. in the past 10 years",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4adabfcc-0cc9-42a3-baa4-567cf71b5eb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"... From the view of absolute trial number and growth, China is leading in areas like CAR-T, large molecule, BsAb and ADC globally, with local companies and talents nurtured with the support of policy makers, PEVCs, MNCs, etc. in the past 10 years ...\" - Medical Lead, a Chinese biotech, Nov. 2022",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-8e00dc66c7ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Accelerated innovative drug developed: China has witnessed a strong growth of early-phase clinical trials, quickly catching up with global innovation capability",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e866f9a6-f193-46bd-b066-64951e4465f9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "CAGR",
      "numberRaw": "47%",
      "numberKind": "percent",
      "actionTitle": "Accelerated innovative drug developed: China has witnessed a strong growth of early-phase clinical trials, quickly catching up with global innovation capability",
      "calloutText": "Strong growth of trial number in China has been fueled particularly by development of innovative drugs",
      "numberScale": null,
      "numberValue": 47,
      "metricFamily": "growth_rate",
      "numberCurrency": null
    }
  ],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "14957684-3318-45b3-a029-fb08dcbf04c2",
      "evidence": "chart/bar-stacked: Number of newly started clinical trials by trial phase (China)",
      "confidence": 0.7
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "51baa571-7733-403a-95a5-92375c7d2dd3",
      "evidence": "list/bullet: Strong growth of trial number in China has been fueled particularly by development of innovative drugs.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 6,
      "beatId": "2e308d53-f564-4d1b-a207-755a279e3246",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}